Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer



In a phase II clinical trial, some patients with metastatic Merkel cell carcinoma whose cancer has progressed despite treatment with chemotherapy had durable tumor responses to the immunotherapy drug avelumab.



Source link

Comments are closed.